key: cord-0912233-27joyjtn authors: Kaczmarek, Radoslaw; El Ekiaby, Magdy; Hart, Daniel P.; Hermans, Cedric; Makris, Mike; Noone, Declan; O’Mahony, Brian; Page, David; Peyvandi, Flora; Pipe, Steven W.; Sannié, Thomas; Schlenkrich, Uwe; Skinner, Mark W.; Srivastava, Alok; Bok, Amanda; Pierce, Glenn F. title: Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders date: 2021-03-02 journal: Haemophilia DOI: 10.1111/hae.14271 sha: a07c35a799e8c69566b875da239159831b22b41d doc_id: 912233 cord_uid: 27joyjtn nan imminent. The success of vaccination campaigns will depend on the number of people effectively vaccinated. The vaccinated population will limit the spread of the SARS-CoV-2 virus. In addition to the logistical challenges of large-scale vaccination, good information, understanding and confidence in the vaccines will determine their adoption by the entire population. Some people have doubts about the efficacy and safety of vaccines or do not acknowledge the need to be vaccinated, either due to legitimate concerns or misinformation. People with haemophilia or other haemorrhagic diseases are no exception to this reality. Here, we present a factual perspective to help healthcare providers and people with bleeding disorders make informed decisions on vaccination. The rationale behind vaccination is to provide every vaccinated person with protection against the SARS-CoV-2 virus. This protection is achieved by stimulating the immune system to produce antibodies against the virus and to develop lymphocytes that will retain memory and the ability to fight off the virus for a long time. Individuals infected with SARS-CoV-2 mount the same kind of response to the virus, but can develop severe and potentially fatal complications. The vaccine acts as a decoy for the immune system, which it stimulates to react and produce protective antibodies without causing the disease. Vaccination consists of exposing the immune system of the recipients to structural proteins of the virus that will elicit a response. This is achieved by administering recombinant viral proteins (protein vaccines), or genetic information encoding those proteins (messenger RNA) that will make the cells of the vaccinated person produce the proteins of the virus (mRNA vaccines), 1 or using another weak- The general selection rules will apply to people with haemophilia. Haemophilia patients belonging to risk groups according to their age, state of health or occupation will be vaccinated as a priority like others in the general population with the same risk profile. 2. There is currently no reason to select a particular type of vaccine for bleeding disorder patients. Some vaccines under development and one that has just been approved in the U.K. and India (Oxford University/AstraZeneca ChAdOx1 nCoV-19 or AZD1222), use an adenovirus. 8 Adenovirus is unrelated to adeno-associated viruses (AAV) and is not being used in haemophilia gene therapy, thus there is no contraindication for using it in the bleeding disorders Any adverse events (eg haematoma, allergic reaction) should be reported to a haemophilia treatment centre. Anticipatory guidance should be given to patients to contact their physician immediately or go to the nearest hospital emergency room right away if they experience an allergic reaction (fever, warmth, redness, itchy skin rash, shortness of breath, or swelling of the face or tongue) as it can be life-threatening. 12, 13 Patients with a history of allergic reactions to extended half-life clotting factor concentrates containing polyethylene glycol (PEG) should discuss vaccine choice with their physician because some vaccines contain PEG as an excipient. 14 People with haemophilia and other bleeding disorders who have had a history of allergic or anaphylactic reactions to blood products, including factor concentrates, plasma and cryoprecipitate, but have not had reactions to previous vaccines, are at no greater risk than the overall population for a reaction to a COVID-19 vaccine. have ready access to haemostatic therapies prior to vaccination. In these cases, make efforts to access WFH Humanitarian Aid programme or other clotting factors if possible. Alternatively, follow the instructions above making sure the smallest possible needle is used and maintain pressure for more than 10 minutes. Willebrand disease (VWD) (regardless of whether they routinely receive prophylaxis or on-demand treatment) the injection should be given after a FVIII or FIX injection, or following a von Willebrand factor-containing injection, respectively. Vaccinations have not been shown to prime FVIII or FIX inhibitor formation in patients with haemophilia. 15 In particular, vaccines against viruses with RNA genomes (influenza, mumps, measles, rubella), like SARS-CoV-2, did not enhance inhibitor formation in an animal model. 16 Mild haemophilia patients with baseline FVIII or FIX levels below 10% may also need haemostatic treatment prior to vaccination and should consult their haemophilia treatment centre. Three decades of messenger RNA vaccine development COVID-19: an overview of the current pharmacological interventions, vaccines, and clinical trials Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine Moderna's COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna In-hospital management of persons with haemophilia and COVID-19: practical guidance Management of COVID-19-associated coagulopathy in persons with haemophilia Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK WFH guidelines for the management of hemophilia Consensus statements on vaccination in patients with haemophilia-results from the Italian haemophilia and vaccinations (HEVA) project Guidelines for the management of hemophilia MASAC Document 221. Recommendations on Administration of Vaccines to Individuals with Bleeding Disorders | National Hemophilia Foundation COVID-19 MRNA Vaccine BNT162b2 Concentrate for Solution for Injection Allergic reactions to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A Confirmation of guidance to vaccination centres on managing allergic reactions following COVID-19 vaccination with the Pfizer/ BioNTech vaccine The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine -United States Vaccination against COVID-19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders